Ron Nixon
Executive Chairman and CEO
Replay available
Sanara MedTech Inc. (NASDAQ: SMTI) Q1 2025 earnings conference call, held 2025-05-14. Replay captured from the company's public earnings webcast.

Executive Chairman and CEO
President and Chief Commercial Officer
President and CEO, Tissue Health Plus
Chief Financial Officer
Analyst, HC Wainwright
Analyst, Cantor Fitzgerald
Welcome to the Sonara MedTech first quarter of 2025 earnings conference call. Please note that this conference call is being recorded and a replay will be available on the investor relations page of the company's website shortly. The company issued its earnings release earlier today. Before we begin, I would like to remind everyone that certain statements on today's call include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For more information about the risks and uncertainties involving forward-looking statements and factors that could cause actual results to differ materially from those projected or implied by forward-looking statements, please see the risk factor set forth in the company's most recent annual report on Form 10-K. This call will also include references to certain non-GAAP measures. Reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings materials available on the investor relations portion of our website. Today's call will be hosted by Ron Nixon, Executive Chairman and CEO, and feature additional remarks from Seth Young, President and Chief Commercial Officer, Sam Mupala, President and CEO of Tissue Health Plus, and Elizabeth Taylor, Chief Financial Officer. I would now like to turn the call over to Mr. Nixon. Please go ahead. Thanks, Operator, and welcome everyone to our first quarter of 2025 earnings call. Let me provide a quick agenda for today's call. I'll start by discussing a few of our financial and operational highlights from the first quarter. Seth will then discuss the commercial execution and progress made in our Scenera Surgical segment and outline the multiple growth opportu...